



**ASX Announcement**  
**20 June 2022**

## **OPTISCAN CEO TO PRESENT AT THE 8<sup>TH</sup> WORLD CONGRESS OF THE INTERNATIONAL ACADEMY OF ORAL ONCOLOGY IN CHICAGO**

### **Highlights:**

- Optiscan Imaging Ltd (ASX:OIL) CEO and Managing Director Prof Camile Farah has been invited to present at the 8<sup>th</sup> World Congress of the International Academy of Oral Oncology (IAOO) in Chicago.
- The IAOO is the largest independent multidisciplinary head and neck cancer Academy in the world, consisting of world-leading clinicians, scientists and surgeons working together to advance medical science into benefits for patients.
- Prof Farah will present on Optical Imaging in Cancer Care on 23<sup>rd</sup> June at 16:45 (CDT), as Optiscan continues to establish greater commercial presence in the global head and neck cancer market.

Optiscan Imaging Limited (ASX: OIL) is pleased to advise that CEO and Managing Director Prof Camile Farah has been invited to present at the 8<sup>th</sup> World Congress of the International Academy of Oral Oncology (IAOO) in Chicago on 23-26 June 2022. Prof Farah's presentation to an audience of world-leading clinical and scientific experts in head and neck cancer titled "*Oral Confocal Laser Endomicroscopy: A Paradigm Shift towards Real-time In Vivo Digital Pathology*" will take place on 23<sup>rd</sup> June at 16:45 (CDT).

Prof Camile Farah stated, "The IAOO is the largest multidisciplinary head and neck cancer Academy in the world, and I am extremely grateful for their invitation to present on the benefits of Optiscan's confocal laser endomicroscopy technology in the detection, diagnosis and management of oral cancer. As a fellow of the Academy, I look forward to meeting delegates and colleagues in Chicago and learning more about their needs as Optiscan prepares to commercialise its unique digital pathology solution in 2023."

This announcement has been authorised for release by the Board of Optiscan.

--ends--

### **For investor queries, please contact:**

Prof Camile Farah  
CEO & Managing Director – Optiscan Imaging Ltd  
E: [cfarah@optiscan.com](mailto:cfarah@optiscan.com)

For more information about our products, visit [www.optiscan.com](http://www.optiscan.com)

### **About Optiscan**

Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, *in-vivo* imaging at the sub-cellular level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

**Phone** (61 3) 9538 3333

**Website** [www.OptiScan.com](http://www.OptiScan.com)

16 Miles St, Mulgrave VIC 3170

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

### **About the International Academy of Oral Oncology (IAOO)**

The IAOO draws together leading clinicians and scientists worldwide working on issues relating to the etiopathogenesis, epidemiology, prevention, and management of oral and perioral tumours and of oral disease in patients with malignancies. Consisting of world-leading clinicians and scientists, the IAOO was established so that advances in medical science could be translated into benefits for patients suffering from head and neck cancer.

### **Disclaimer**

*All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of OptiScan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of OptiScan that could cause actual results to differ from the results expressed or anticipated in these statements.*